Cutting-edge approaches to B-cell depletion in autoimmune diseases

• Published in: Frontiers in immunology Vol. 15; p. 1454747
• Main Authors: Robinson, William H, Fiorentino, David, Chung, Lorinda, Moreland, Larry W, Deodhar, Malavika, Harler, Mary Beth, Saulsbery, Carrie, Kunder, Rebecca
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 09.10.2024
• Subjects: Animals; Antibodies, Bispecific - immunology; Antibodies, Bispecific - therapeutic use; Antibodies, Monoclonal - immunology; Antibodies, Monoclonal - therapeutic use; autoimmune disease; Autoimmune Diseases - immunology; Autoimmune Diseases - therapy; B-cell depletion therapy; B-Lymphocytes - immunology; effector function-enhanced monoclonal antibodies; Humans; Immunology; Immunotherapy, Adoptive - methods; imvotamab; Lymphocyte Depletion - methods; Receptors, Chimeric Antigen - genetics; Receptors, Chimeric Antigen - immunology; T-cell engager; T-Lymphocytes - immunology; effector function-enhanced monoclonal antibodies; T-cell engager; autoimmune disease; B-cell depletion therapy; imvotamab
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2024.1454747

B-cell depletion therapy (BCDT) has been employed to treat autoimmune disease for ~20 years. Immunoglobulin G1 (IgG1) monoclonal antibodies targeting CD20 and utilizing effector function (eg, antibody-dependent cellular cytotoxicity, complement-dependent cytotoxicity, antibody-dependent cellular phagocytosis) to eliminate B cells have historically been the predominant therapeutic approaches. More recently, diverse BCDT approaches targeting a variety of B-cell surface antigens have been developed for use in hematologic malignancies, including effector-function-enhanced monoclonal antibodies, chimeric antigen receptor T-cell (CAR-T) treatment, and bispecific T-cell engagers (TCEs). The latter category of antibodies employs CD3 engagement to augment the killing of target cells. Given the improvement in B-cell depletion observed with CAR-T and TCEs compared with conventional monospecific antibodies for treatment of hematologic malignancies and the recent case reports demonstrating therapeutic benefit of CAR-T in autoimmune disease, there is potential for these mechanisms to be effective for B-cell-mediated autoimmune disease. In this review, we discuss the various BCDTs that are being developed in autoimmune diseases, describing the molecule designs, depletion mechanisms, and potential advantages and disadvantages of each approach as they pertain to safety, efficacy, and patient experience. Additionally, recent advances and strategies with TCEs are presented to help broaden understanding of the potential for bispecific antibodies to safely and effectively engage T cells for deep B-cell depletion in autoimmune diseases.